Modera Wealth Management LLC Buys 10,368 Shares of Bristol Myers Squibb Company $BMY

Modera Wealth Management LLC raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 54.8% during the 3rd quarter, Holdings Channel reports. The fund owned 29,285 shares of the biopharmaceutical company’s stock after acquiring an additional 10,368 shares during the period. Modera Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $1,827,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $27,000. Addison Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $32,000. Groupe la Francaise increased its stake in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 501 shares during the period. Arlington Trust Co LLC bought a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $35,000. Finally, Kilter Group LLC bought a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $35,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $62.46 on Monday. The company’s 50 day simple moving average is $62.80 and its 200 day simple moving average is $59.94. The stock has a market capitalization of $127.67 billion, a price-to-earnings ratio of 13.85, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a 1 year low of $45.20 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the previous year, the business earned $1.63 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.40 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Wall Street Analyst Weigh In

Several research firms recently weighed in on BMY. Leerink Partners cut Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $73.00 to $59.00 in a report on Monday, October 5th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Truist Financial set a $70.00 price objective on Bristol Myers Squibb in a research report on Friday. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Finally, Raymond James Financial initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.46.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.